K. Shmanko

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

M. Ebert, H. Heinzl, J. Dufour, 2021, Journal of hepatology.

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience

A. Vogel, J. Marquardt, A. Saborowski, 2022, Therapeutic advances in medical oncology.

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

M. Ebert, J. Dufour, L. Rimassa, 2022, JHEP reports : innovation in hepatology.

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort

M. Trauner, A. Vogel, A. Weinmann, 2022, ESMO open.

Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

R. Greil, C. Strassburg, A. Vogel, 2022, Liver Cancer.

Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort

A. Saborowski, P. Jeliazkova, B. Scheiner, 2024, Hepatology communications.